# HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Source: https://onco.cc/trials/nct06855069/  
OnCo record `nct06855069` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing HS-20089 in ovarian cancer, now recruiting.

## Summary

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06855069, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Multi-centre, Randomised, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Planned enrolment is 468 participants (estimated). The study started in 2025-03-13 and primary completion is expected in 2027-03-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT06855069
- Phase: 3
- Setting: A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Sponsor: Hansoh BioMedical R&D
- Enrolled: 468

## Sources

- ClinicalTrials.gov NCT06855069: https://clinicaltrials.gov/study/NCT06855069

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-resistant ovarian cancer](https://onco.cc/cancers/platinum-resistant-ovarian-cancer/)
- drugs: [HS-20089](https://onco.cc/drugs/hs-20089/)
- companies: [Hansoh Pharmaceutical](https://onco.cc/companies/hansoh-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06855069.json